Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled Phase III Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled Phase III Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Siltartoxatug (Primary) ; Tetanus immune globulin
  • Indications Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Trinomab Biotech; Zhuhai Trinomab Pharmaceutical

Most Recent Events

  • 01 Dec 2025 According to the Zhuhai Trinomab Pharmaceutical media release, approved for marketing through the priority review and approval procedure by China NMPA. This product is indicated for emergency prophylaxis of tetanus in adults.It is a recombinant anti-tetanus toxin monoclonal antibody, which provides passive immunity primarily by binding to the AB fragment of tetanus toxin.
  • 20 Nov 2025 According to Trinomab Pharmaceuticalmedia release, Trinomab Biotech has changed its name to Zhuhai Trinomab Pharmaceuticals.
  • 01 Aug 2025 Primary endpoint (Proportion of participants with an increase of anti-tetanus neutralizing antibody titers ( titers) over protective level) has been met, as per results published in the Nature Medicine.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top